PharmAla Partners with Clariti Strategic Advisors™
08 nov. 2023 08h55 HE
|
PharmAla Biotech
PharmAla signs long-term partnership with Clariti Strategic Partners as its investment banking and advisory firm
PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa
07 nov. 2023 08h55 HE
|
PharmAla Biotech
PharmAla completes the historic first shipment of MDMA and Psilocybin to its Australian Joint Venture, Cortexa, for use in commercial patient treatments
Optimi Health Welcomes Dr. Preston A. Chase as New Chief Science Officer
07 nov. 2023 07h30 HE
|
Optimi Health Corp.
Optimi Health Introduces New Chief Science Officer Dr. Preston A. Chase.
Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer
06 nov. 2023 07h00 HE
|
Sunstone Therapies
Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer Phase 2 study to examine safety and efficacy of up to two...
Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing
02 nov. 2023 07h30 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation...
Lucy Scientific Discovery’s Alternative Mental Health Treatments to Provide Opportunity to Improve Mental Health
18 oct. 2023 07h00 HE
|
Lucy Scientific Discovery Inc.
From herbal remedies to psychedelics, like psilocybin and MDMA, Lucy Scientific is working to provide the ingredients for groundbreaking mental health ther
PS2023: The Virtual Trip Unveils Latest Video Release Featuring Michael Pollan, Melissa Etheridge, and More
09 oct. 2023 15h13 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
PS2023: The Virtual Trip adds 40+ conference sessions in MAPS’ ongoing effort to provide broad access to Psychedelic Science 2023.
The Future of Psychedelic Access in Canada: PsyCan Releases White Paper Reviewing Regulatory Options for Psychedelics
03 oct. 2023 07h00 HE
|
Psychedelics Canada
PsyCan, the trade association for the for-profit psychedelic medicine industry, releases a white paper on how Health Canada can improve access to therapies
Sunstone Therapies Announces Expansion of Innovative Dyad Study
03 oct. 2023 07h00 HE
|
Sunstone Therapies
Sunstone Therapies Announces Expansion of Innovative Dyad Study Expansion of Phase 2 pilot trial to assess MDMA-assisted therapy for adjustment disorder in dyads of patients with cancer and a...
PharmAla Receives First Office Action for PharmAla-1 PCT Filing
25 sept. 2023 08h55 HE
|
PharmAla Biotech
PharmAla has recieved a positive First Office Action on its novel P-1 Molecule from the Patent Cooperation Treaty